45 completed, 13 terminated, 3 withdrawn, 2 active not recruiting. 63 Phase 2, 22 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 63 | Completed 45, Terminated 13, Withdrawn 3, Active not recruiting 2 |
| Phase 1 | 22 | Completed 13, Terminated 5, Active not recruiting 2, Withdrawn 2 |
Follow Recurrent Marginal Zone Lymphoma: new trials by email Literature Review of Recurrent Marginal Zone Lymphoma trials Research Report on Recurrent Marginal Zone Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Polatuzumab Vedotin, Rituximab, Rituximab and Hyaluronidase Human - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma | Phase 2 | Terminated | Academic and Community Cancer Research United | 3 | 2021-04-01 | 2024-09-19 |
| Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies Nivolumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Completed | University of Washington | 20 | 2020-06-05 | 2026-06-26 |
| Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma Carmustine, Cytarabine, Etoposide - Hematopoietic Cell Transplantation Recipient, Recurrent Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 19 | 2018-09-10 | 2025-05-14 |
| Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma Carfilzomib, Laboratory Biomarker Analysis, Rituximab - Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma | Phase 2 | Terminated | University of Washington | 4 | 2017-12-18 | 2020-01-18 |
| A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas Chimeric Antigen Receptor T-Cell Therapy, Cyclophosphamide, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Active not recruiting | Fred Hutchinson Cancer Center | 53 | 2017-12-05 | 2026-06-22 |
| Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma Cryosurgery, Dendritic Cell Therapy, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | Mayo Clinic | 11 | 2017-08-15 | 2026-05-04 |
| Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma Selinexor - Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Barbara Ann Karmanos Cancer Institute | 43 | 2017-06-20 | 2026-10-23 |
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Nivolumab - Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma | Phase 1 / Phase 2 | Completed | David Bond, MD | 36 | 2017-02-14 | 2026-09-23 |
| Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma rituximab, lenalidomide, romidepsin - B-cell Adult Acute Lymphoblastic Leukemia, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Phase 1 / Phase 2 | Withdrawn | Mayo Clinic | 2016-10-01 | 2016-08-11 | |
| Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia | Phase 2 | Completed | Mayo Clinic | 65 | 2015-02-19 | 2026-06-24 |
| A Phase I/II Study of Intratumoral Injection of SD-101 Ipilimumab, SD-101, Radiation therapy - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 / Phase 2 | Completed | Robert Lowsky | 9 | 2014-09-01 | 2019-11-27 |
| Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma Laboratory Biomarker Analysis, Lenalidomide, Obinutuzumab - Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2014-05-27 | 2025-06-24 |
| Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies cyclophosphamide, fludarabine phosphate, mycophenolate mofetil - Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome | Phase 2 | Withdrawn | University of Medicine and Dentistry of New Jersey | 2014-01-01 | 2016-07-14 | |
| Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies vorinostat, tacrolimus, cyclosporine - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2013-06-01 | 2018-07-24 |
| Alisertib With and Without Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma alisertib, rituximab, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Terminated | Ohio State University Comprehensive Cancer Center | 14 | 2013-05-21 | 2018-06-06 |
| Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies therapeutic allogeneic lymphocytes, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 2 | Completed | University of Chicago | 77 | 2013-04-04 | 2019-08-07 |
| Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas brentuximab vedotin, rituximab, laboratory biomarker analysis - Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma | Phase 1 / Phase 2 | Terminated | Northwestern University | 20 | 2013-03-05 | 2021-09-01 |
| Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant lenalidomide, rituximab, pharmacological study - Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 3 | 2012-05-01 | 2017-07-27 |
| Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies fludarabine phosphate, melphalan, total-body irradiation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Roswell Park Cancer Institute | 94 | 2012-02-28 | 2019-09-24 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
Showing 20 of 63. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (63) · Lymphoma, Follicular (62) · Leukemia, Lymphocytic, Chronic, B-Cell (52) · Lymphoma, Mantle-Cell (51) · Lymphoma, Large B-Cell, Diffuse (47) · Waldenstrom Macroglobulinemia (47) · Lymphoma, Non-Hodgkin (46) · Burkitt Lymphoma (38) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (38) · Lymphoma, Large-Cell, Immunoblastic (35) · Hodgkin Disease (33) · Lymphoma, T-Cell, Cutaneous (28) · Mycosis Fungoides (28) · Sezary Syndrome (28) · Lymphoma, Large-Cell, Anaplastic (25)
Hemic and Lymphatic Diseases (63) · Immune System Diseases (63) · Immunoproliferative Disorders (63) · Lymphatic Diseases (63) · Lymphoproliferative Disorders (63) · Neoplasms by Histologic Type (63) · Lymphoma (62) · Neoplasms (62) · Hematologic Diseases (60) · Lymphoma, B-Cell (58) · Leukemia (54) · Blood Protein Disorders (53) · Cardiovascular Diseases (53) · Hemorrhagic Disorders (53) · Hemostatic Disorders (53)
Rituximab (20) · fludarabine phosphate (16) · Mycophenolic Acid (15) · Whole-Body Irradiation (15) · Peripheral Blood Stem Cell Transplantation (14) · Cyclophosphamide (11) · Cyclosporine (10) · Tacrolimus (10) · Busulfan (5) · Lenalidomide (5) · Calcium Dobesilate (4) · Dexamethasone (4) · Etoposide (4) · Methotrexate (4) · Sirolimus (4)
Fred Hutchinson Cancer Center (19) · National Cancer Institute (NCI) (17) · Mayo Clinic (5) · University of Washington (4) · Case Comprehensive Cancer Center (2) · Ohio State University Comprehensive Cancer Center (2) · Roswell Park Cancer Institute (2) · Academic and Community Cancer Research United (1) · Barbara Ann Karmanos Cancer Institute (1) · City of Hope Medical Center (1) · David Bond, MD (1) · M.D. Anderson Cancer Center (1) · Northwestern University (1) · Robert Lowsky (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (62) · Italy (5) · Germany (2) · Denmark (1)
Ajay Gopal (5) · Brenda Sandmaier (4) · David Maloney (4) · Anas Younes (2) · Sonali Smith (2) · Thomas Witzig (2) · Adam Petrich, MD (1) · Andre Goy (1) · Barbara Pro (1) · Brenda Cooper (1) · Brenda Cooper, MD (1) · Catherine S Diefenbach (1) · David Bond, MD (1) · Dipenkumar Modi, M.D. (1) · Elizabeth Christian (1)
PMID 32499241, PMID 19900571, PMID 20837940, PMID 21300924, PMID 21508413, PMID 24241210, PMID 25085357, PMID 26213141, PMID 26764356, PMID 28314788, PMID 28424162, PMID 30454872, PMID 31481800, PMID 33785483, PMID 34320785, PMID 34515338, PMID 34780125, PMID 39161543
P30CA015704 (11), P30CA015083 (5), P01CA018029 (4), N01CM17003 (3), N01CM62202 (3), P01CA078902 (3), N01CM62201 (2), P30CA014599 (2), P50CA097274 (2), U01CA076576 (2), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM17101 (1), N01CM17107 (1)